Shares in Acorda Therapeutics (NSDQ:ACOR) jumped this morning after the company reported that its inhaled Parkinson’s drug significantly improved motor function in a Phase III trial.
The investigational drug is being studied as a therapy for people with Parkinson’s disease experiencing “off” periods, or a re-emergence of symptoms.
The Phase III Span-Pd trial enrolled 339 patients with Parkinson’s disease and found that 84 milligrams of CVT-301 improved motor function compared to placebo, measured at 30 minutes post-dose after 12 weeks.
Get the full story at our sister site, Drug Delivery Business News.
The post Inhaled Parkinson’s treatment improves motor function in Phase III appeared first on MassDevice.